Examkin

Soru

Zorluk: ZorMonitoring and Treatment Evaluation

An inpatient with ischemic cardiomyopathy and a left ventricular ejection fraction of 22% is preparing for hospital discharge following treatment for an acute decompensation. Over the past 72 hours, his volume status has been optimized with intravenous furosemide, and he was successfully transitioned to an oral diuretic regimen yesterday. His pre-admission medication list, which the care team is reviewing, includes carvedilol 25 mg twice daily, spironolactone 25 mg daily, and lisinopril 40 mg daily. To further reduce mortality risk, the attending physician decides to discontinue lisinopril and initiate sacubitril-valsartan therapy. The patient's most recent basic metabolic panel reveals a serum creatinine of 1.1 mg/dL and a serum potassium level of 4.6 mEq/L. Which of the following principles must be integrated into this patient's treatment transition and ongoing monitoring plan? (Select 2)

  1. A mandatory 36-hour washout period must elapse after the final dose of the current angiotensin-converting enzyme inhibitor before administering the first dose of the new therapy.Cevap
  2. Future assessments of volume overload and heart failure severity in the outpatient clinic should rely on N-terminal pro-B-type natriuretic peptide (NT-proBNP) rather than standard B-type natriuretic peptide (BNP).Cevap
  3. C
    The new pharmacotherapy should be initiated concurrently with a scheduled dose increase of spironolactone to maximize neurohormonal blockade prior to discharge.
  4. D
    Routine serial monitoring of serum creatine kinase levels is required during the first four weeks of therapy to detect early-onset myopathy.
  5. E
    The planned transition must be aborted because the patient's concurrent use of a beta-blocker constitutes an absolute contraindication to neprilysin inhibition.

Cevap

The essential steps in the treatment transition and monitoring plan are to ensure a 36-hour washout period after stopping the ACE inhibitor and to utilize NT-proBNP instead of BNP for future heart failure surveillance.
Transitioning a patient from an angiotensin-converting enzyme (ACE) inhibitor to an angiotensin receptor-neprilysin inhibitor (ARNI) requires a strict 36-hour washout period. ACE inhibitors and neprilysin inhibitors both block the degradation of bradykinin; co-administration or rapid succession without a washout leads to excessive bradykinin accumulation and a profound risk of angioedema. Additionally, for long-term monitoring, the clinician must understand that neprilysin inhibition prevents the breakdown of B-type natriuretic peptide (BNP). Consequently, BNP levels become artificially elevated and lose their diagnostic utility for assessing heart failure exacerbations. N-terminal pro-B-type natriuretic peptide (NT-proBNP) is not a substrate for neprilysin and must be used instead to accurately track the patient's volume status and disease trajectory.

Adım Adım Çözüm

1
Analyze the proposed medication change
The patient is being transitioned from lisinopril (an ACE inhibitor) to sacubitril-valsartan (an Angiotensin Receptor-Neprilysin Inhibitor [ARNI]).
Identifying the specific drug classes involved dictates the required safety protocols for the transition.
2
Determine the necessary transition protocol to prevent adverse effects
A 36-hour washout period must be instituted between the last dose of lisinopril and the first dose of sacubitril-valsartan.
Both ACE inhibitors and neprilysin inhibitors prevent the breakdown of bradykinin. Overlapping these medications drastically increases the risk of life-threatening angioedema.
3
Evaluate the impact of the new medication on routine laboratory monitoring
Future biomarker monitoring must rely on NT-proBNP instead of BNP.
Sacubitril inhibits neprilysin. Because neprilysin is the enzyme responsible for clearing standard BNP, BNP levels will be artificially elevated in patients taking this drug. NT-proBNP is cleared by different mechanisms and remains an accurate reflection of ventricular stretch and heart failure status.

Anahtar Kavram

When initiating an ARNI (sacubitril-valsartan), a 36-hour washout period is required after stopping an ACE inhibitor to prevent angioedema, and NT-proBNP must replace standard BNP as the primary biomarker for monitoring heart failure status.
Bu soruyu puanla

Konular

Monitoring and Treatment Evaluation

Bu konudan daha fazla soru